Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegvaliase - BioMarin Pharmaceutical

Next Previous
Drug Profile

Pegvaliase - BioMarin Pharmaceutical

Alternative Names: BMN-165; Palynziq; PEG-PAL; Pegvaliase-pqpz; PEGylated phenylalanine ammonia lyase; Pegylated recombinant Anabaena variabilis phenylalanine ammonia lyase; PEGylated recombinant phenylalanine ammonia lyase; Phenylase; rAvPAL-PEG

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IBEX Technologies
  • Developer BioMarin Pharmaceutical
  • Class Ammonia lyases; Enzymes; Recombinant proteins
  • Mechanism of Action Phenylalanine ammonia lyase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Phenylketonuria

Most Recent Events

  • 02 Apr 2025 Registered for Phenylketonuria (In adolescents, In adults, In the elderly) in Brazil, Canada (SC)
  • 02 Apr 2025 Efficacy and adverse events data from a phase III PEGASUS trial in Phenylketonuria released by BioMarin Pharmaceutical
  • 19 Feb 2025 BioMarin Pharmaceutical plans to submit regulatory filingsfor label expansion for Phenylketonuria (In adolescents) in USA and Europe (SC, injection) in second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top